MCL cells are malignant B cells that express antigens, such as CD193,4

  • CD19 is a cell-surface protein that regulates the immune response5
  • CD19 is only expressed in B cells and is expressed across the B-cell lineage, including the abnormal naïve B cells associated with MCL4-6
  • The moderate-to-high expression of CD19 in MCL, and its lack of expression in essential tissues, make CD19 an attractive therapeutic target4,5

TECARTUS is a single-infusion, autologous cellular therapy designed for R/R MCL, a CD19-expressing B-cell malignancy with a high circulating tumor burden1,2,7,8

TECARTUS® mechanism of action
  1. Target Binding Domain—binds to CD19 on the surface of B cells1,9

  2. CD28 Co-stimulatory Domain

    • CD28, the co-stimulatory domain in TECARTUS, augments T-cell receptor signaling to drive cytokine production and T-cell proliferation1,9
  3. CD3-ζ Activation Domain—activates T cell1,9

TECARTUS binds to CD19-expressing cancer cells and normal B cells1

  • Upon engagement with target cells, the co-stimulatory domains activate downstream signaling cascades that result in
    • T-cell activation, proliferation, and acquisition of effector functions
    • Secretion of inflammatory cytokines and chemokines
  • This sequence of events leads to killing of CD19-expressing cells

TECARTUS is manufactured to meet the needs of patients with R/R MCL by removing circulating tumor cells2

TECARTUS manufacturing process: successfully and reliably manufactured for patients with R/R MCL1



turnaround time

from leukapheresis
to product delivery
(range: 11 to 28 days)


success rate*




*In the ZUMA-2 trial, 3 patients did not receive TECARTUS due to manufacturing failure.1

CD=cluster of differentiation; MCL=mantle cell lymphoma; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. 3. Dreyling M, on behalf of the European MCL Network. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book. 2014;34:191-198. 4. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-276. 5. Blanc V, Bousseau A, Caron A, et al. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448-6458. 6. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:1-20. 7. Argatoff LH, Connors JM, Klasa RJ, Horseman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89(6):2067-2078. 8. Gu J, Huh YO, Jiang F, et al. Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings. Mod Pathol. 2004;17(5):553-560. 9. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(suppl 1):S3-S9.